These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 33399071)

  • 1. Prognostic model for risk stratification of de novo metastatic nasopharyngeal carcinoma patients treated with chemotherapy followed by locoregional radiotherapy.
    Li WZ; Hua X; Xie DH; Liang H; Liu GY; Xia WX; Xiang YQ
    ESMO Open; 2021 Feb; 6(1):100004. PubMed ID: 33399071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Locoregional radiotherapy improves survival outcomes in de novo metastatic nasopharyngeal carcinoma treated with chemoimmunotherapy.
    Hu YJ; Lu TZ; Zhang H; Fang M; Chen BJ; Guo QJ; Lin SJ; Feng P; Wang Y; Jiang TC; Gong XC; Pan JJ; Li JG; Xia YF
    ESMO Open; 2023 Oct; 8(5):101629. PubMed ID: 37660406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identifying optimal candidates for local treatment of the primary tumor among patients with de novo metastatic nasopharyngeal carcinoma: a retrospective cohort study based on Epstein-Barr virus DNA level and tumor response to palliative chemotherapy.
    Sun XS; Liu LT; Liu SL; Guo SS; Wen YF; Xie HJ; Tang QN; Liang YJ; Li XY; Yan JJ; Ma J; Chen QY; Tang LQ; Mai HQ
    BMC Cancer; 2019 Jan; 19(1):92. PubMed ID: 30665378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subdivision of de-novo metastatic nasopharyngeal carcinoma based on tumor burden and pretreatment EBV DNA for therapeutic guidance of locoregional radiotherapy.
    Yang JH; Sun XS; Xiao BB; Liu LT; Guo SS; Liang JD; Jia GD; Tang LQ; Chen QY; Mai HQ
    BMC Cancer; 2021 May; 21(1):534. PubMed ID: 33975558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proposed prognostic subgroups and facilitated clinical decision-making for additional locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma: a retrospective study based on recursive partitioning analysis.
    Yao Y; Sun X; Huang H; Wang Z; Fang X; Chen M; Chen Z; Weng H; Guo C; Hong H; Huang H; Lin T
    Radiat Oncol; 2023 Jan; 18(1):15. PubMed ID: 36681832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of capecitabine as maintenance therapy in de novo metastatic nasopharyngeal carcinoma: A propensity score matching study.
    Sun XS; Liu SL; Liang YJ; Chen QY; Li XY; Tang LQ; Mai HQ
    Cancer Commun (Lond); 2020 Jan; 40(1):32-42. PubMed ID: 32112522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk-adapted locoregional radiotherapy strategies based on a prognostic nomogram for de novo metastatic nasopharyngeal carcinoma patients treated with chemoimmunotherapy.
    Chen Y; Chen C; Peng H; Lin S; Pan J; Zheng H; Zong J; Lin C
    Sci Rep; 2024 Feb; 14(1):3950. PubMed ID: 38366057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effective of metastasis-directed therapy for de novo metastatic nasopharyngeal carcinoma: A propensity score matched analysis.
    Liu GY; Li Z; Chen XX; Xia WX; Yao HR; Xiang YQ
    Head Neck; 2023 Oct; 45(10):2571-2579. PubMed ID: 37554098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subdivision of Nasopharyngeal Carcinoma Patients with Bone-Only Metastasis at Diagnosis for Prediction of Survival and Treatment Guidance.
    Sun XS; Liang YJ; Liu SL; Chen QY; Guo SS; Wen YF; Liu LT; Xie HJ; Tang QN; Li XY; Yan JJ; Tang LQ; Mai HQ
    Cancer Res Treat; 2019 Oct; 51(4):1259-1268. PubMed ID: 30653745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrating Baseline Nutritional and Inflammatory Parameters with Post-Treatment EBV DNA Level to Predict Outcomes of Patients with De Novo Metastatic Nasopharyngeal Carcinoma Receiving Chemotherapy Combination PD-1 Inhibitor.
    Guo J; Yang Q; Jiang Q; Gu LW; Lin HX; Guo L
    Nutrients; 2023 Oct; 15(19):. PubMed ID: 37836546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recursive partitioning analysis model for de novo metastatic nasopharyngeal carcinoma treated with locoregional radiotherapy following chemoimmunotherapy.
    Wen D; Gu L; Long H; Liu S; Luo M; Li R; Liu R; Lin J; Jin J; Xiong L; Tang L; Mai H; Liu L; Liang Y; Chen Q; Guo S
    ESMO Open; 2024 Nov; 9(11):103960. PubMed ID: 39426079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing the treatment mode for de novo metastatic nasopharyngeal carcinoma with bone-only metastasis.
    Lin C; Lin S; Zhu L; Lin S; Pan J; Xu Y
    BMC Cancer; 2022 Jan; 22(1):35. PubMed ID: 34983459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identifying the optimal candidates for locoregional radiation therapy in patients with de novo metastatic nasopharyngeal carcinoma.
    Xu H; Lu L; Lu T; Xu Y; Zong J; Huang C; Lin F; Zheng Y; Lin C; Lin S; Qiu S; Pan J; Lin S; Guo Q
    Head Neck; 2021 Sep; 43(9):2602-2610. PubMed ID: 33904617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic value of pretreatment
    Gu LW; Zhang X; Zhang J; Xiao BB; Wu LP; Tang LQ; Guo L; Liu LT
    Oral Oncol; 2024 Sep; 156():106928. PubMed ID: 38968724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of pre-treatment FDG PET/CT SUVmax for metastatic lesions in de novo metastatic nasopharyngeal carcinoma following chemotherapy and locoregional radiotherapy.
    Yan W; Sun C; Ou X; Hu C
    Cancer Imaging; 2023 Feb; 23(1):21. PubMed ID: 36829263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a Prognostic Model to Identify the Suitable Definitive Radiation Therapy Candidates in de Novo Metastatic Nasopharyngeal Carcinoma: A Real-World Study.
    Li WZ; Lv SH; Liu GY; Liang H; Guo X; Lv X; Liu KY; Qiang MY; Chen X; Gu SZ; Xie CQ; Xia WX; Xiang YQ
    Int J Radiat Oncol Biol Phys; 2021 Jan; 109(1):120-130. PubMed ID: 32853711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. M1 stage subdivisions based on
    Qiu HZ; Zhang X; Liu SL; Sun XS; Mo YW; Lin HX; Lu ZJ; Guo J; Tang LQ; Mai HQ; Liu LT; Guo L
    Ther Adv Med Oncol; 2022; 14():17588359221118785. PubMed ID: 35983026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship of circulating tumor cells and Epstein-Barr virus DNA to progression-free survival and overall survival in metastatic nasopharyngeal carcinoma patients.
    You R; Liu YP; Lin M; Huang PY; Tang LQ; Zhang YN; Pan Y; Liu WL; Guo WB; Zou X; Zhao KM; Kang T; Liu LZ; Lin AH; Hong MH; Mai HQ; Zeng MS; Chen MY
    Int J Cancer; 2019 Nov; 145(10):2873-2883. PubMed ID: 31044420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Individualized concurrent chemotherapy by pretreatment plasma Epstein-Barr viral DNA in II-III stage nasopharyngeal carcinoma: A propensity score matching analysis using a large cohort.
    Sun XS; Chen WH; Liu SL; Liang YJ; Chen QY; Guo SS; Wen YF; Liu LT; Xie HJ; Tang QN; Li XY; Yan JJ; Mai HQ; Tang LQ
    Cancer Med; 2019 Aug; 8(9):4214-4225. PubMed ID: 31210417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor residue in patients with stage II-IVA nasopharyngeal carcinoma who received intensity-modulated radiation therapy: development and validation of a prediction nomogram integrating postradiotherapy plasma Epstein-Barr virus deoxyribonucleic acid, clinical stage, and radiotherapy dose.
    Huang YY; Zhou JY; Zhan ZJ; Ke LR; Xia WX; Cao X; Cai ZC; Deng Y; Chen X; Zhang LL; Huang HY; Guo X; Lv X
    BMC Cancer; 2023 May; 23(1):410. PubMed ID: 37149594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.